Inducible Germline‑Reprogramming Suite Coupled with Selection Yields Full Somatic Epigenetic Reset

Hypothesis: Simultaneous, transient expression of the somatic reprogramming factors OSK together with germline‑specific protectors DPPA2/4, Nanog, and Stella/PGC7, followed by a short pulse of p53‑mediated apoptosis targeting cells that retain residual epigenetic marks, will achieve a germline‑level epigenomic reset in somatic tissues without compromising identity or increasing tumorigenic risk.

Rationale: Germline cells maintain epigenetic fidelity across generations by deploying parallel, redundant reprogramming pathways—global DNA demethylation via 5‑hmC conversion, histone demethylases such as SPR‑5/LSD1, and protective factors that safeguard lineage‑specific enhancers (DPPA2/4, Nanog, Stella) [1][2][5]. Somatic partial reprogramming with OSK alone activates only one of these pathways, reversing 43‑65 % of age‑altered transcription and resetting methylation clocks incompletely [3][4]. The missing germline protectors likely explain why OSK fails to erase parental epigenetic memory fully and why somatic rejuvenation remains incomplete. Adding these protectors should restore the enhancer landscape fidelity that OSK lacks, while a selection step removes incompletely reprogrammed cells, mirroring the ruthless culling that occurs in germline bottlenecks.

Testable predictions: 1) In mouse liver hepatocytes, inducible OSK + DPPA2/4 + Nanog + Stella expression for 48 h will reduce epigenetic age (measured by Horvath‑mouse clock) to levels comparable to newborn tissue, exceeding the reduction seen with OSK alone. 2) Residual methylation at imprinting control regions (e.g., H19, Igf2) will be significantly lower after the combined treatment than after OSK alone. 3) A subsequent 24 h pulse of MDM2‑inhibitor‑activated p53 will selectively eliminate cells retaining >10 % of age‑associated methylation at these loci, as shown by single‑cell bisulfite sequencing. 4) Treated mice will exhibit improved functional readouts (e.g., glucose tolerance, serum albumin) without increased tumorigenesis over a 6‑month period, whereas OSK‑only or protector‑only groups will show either incomplete functional rescue or higher tumor incidence.

Falsifiability: If the combined OSK + protector regimen fails to lower epigenetic age beyond OSK alone, or if p53‑mediated selection does not preferentially clear incompletely reprogrammed cells, the hypothesis is refuted. Likewise, observation of elevated tumor formation or loss of hepatocyte identity (e.g., loss of Hnf4a expression) would falsify the claim that the strategy yields a safe, germline‑grade reset.

Experimental outline: Use AAV9‑mediated, doxycycline‑inducible constructs for OSK, DPPA2/4, Nanog, and Stella in adult Alb‑CreERT2 mice; administer doxycycline for 48 h, then give a short course of nutlin‑3 to activate p53. Assess epigenetic age, transcriptome, imprinting methylation, liver function, and tumor burden at 1, 3, and 6 months post‑treatment. Include controls: OSK alone, protectors alone, and vehicle.

By coupling the germline’s reprogramming toolkit with a selection mechanism that mimics its natural culling, we directly test whether supplying somatic cells a "germline‑grade editing budget" can restore youthful epigenetics without the trade‑offs seen in current partial reprogramming approaches.